做多
做多
做多
做多
做多
一天一家A股公司高管：摩尔线程创始人、董事长兼总经理是张建中一、基本背景：科班出身，扎根IT行业
张建中1966年出生于江苏南京，本科毕业于南京理工大学计算机系，后进入原冶金部自动化研究院深造，获得硕士学位。科班背景为他后续在IT领域的深耕奠定了技术基础。
二、早期职业经历：从科研到企业，积累行业经验
张建中的职业起点是冶金自动化研究设计院国家计算机实验室，1990年5月至1992年3月担任高级研究员，期间参与了计算机实验室的科研项目，积累了早期的技术研究经验。
1992年4月，他加入中国惠普有限公司，担任产品总经理，负责惠普计算机系统产品的市场推广与管理，积累了企业运营与产品管理的经验。
2001年6月，张建中转投戴尔（中国）有限公司，担任全球客户部总经理，负责戴尔全球客户的产品销售与客户关系管理，进一步拓展了其在IT企业高层管理的经验。
三、英伟达时期：开拓中国市场，成为全球副总裁
2005年，张建中加入英伟达（NVIDIA），开启了其在GPU领域的核心职业生涯。在英伟达期间，他担任全球副总裁、大中华区总经理，负责英伟达中国市场的战略规划与业务拓展。
其核心贡献在于开拓建立GPU在中国的完整生态系统：通过推动英伟达GPU与中国本土软件、硬件厂商的合作，以及针对中国市场推出定制化产品，使英伟达中国GPU市场占有率从2008年的不足50%大幅提升至2020年的80%，成为中国GPU市场的主导品牌。这一成绩不仅巩固了英伟达在全球GPU领域的地位，也让张建中成为GPU行业的“中国通”，积累了丰富的本土市场资源与生态构建经验。
四、创立摩尔线程：怀揣“国产GPU梦”，开启创业之路
2020年，张建中从英伟达离职，创立摩尔线程智能科技（北京）股份有限公司（以下简称“摩尔线程”），并担任董事长兼总经理。其创业的初心是“造中国人自己的全功能GPU”，解决中国GPU产业“卡脖子”的问题。
摩尔线程成立后，张建中凭借其在GPU行业的深厚积累，带领团队快速推进研发：2021年11月推出首颗全功能GPU芯片“苏堤”，2022年3月发布MUSA统一系统架构，2022年11月推出业内首款国产游戏显卡MTT S80，2023年9月发布新一代全功能GPU芯片“曲院”及AI训推一体计算卡MTT S4000，逐步构建起覆盖3D图形渲染、AI计算、科学计算等多重能力的全功能GPU产品体系。
在张建中的领导下，摩尔线程发展迅速：2023年10月被美国商务部列入实体清单（限制其获取美国技术与产品），但公司通过调整供应链策略（如采用国内代工）推进自主可控；2025年12月登陆科创板，开盘当日股价涨超400%，市值突破2800亿元，成为“国产GPU第一股”。
五、核心能力与贡献：生态构建与本土化经验
张建中的核心竞争力在于GPU生态构建能力与本土化市场经验：
生态构建：在英伟达期间，他推动英伟达CUDA生态在中国的普及，积累了丰富的软件生态资源；创立摩尔线程后，他延续这一思路，推动MUSA架构与国内软件生态（如游戏引擎、AI框架）的兼容，降低开发者迁移成本。
本土化经验：他熟悉中国市场的需求（如游戏、AI、工业设计等领域的GPU需求），能够针对本土市场推出定制化产品（如MTT S80针对游戏玩家，MTT S4000针对AI企业），这也是摩尔线程能够快速占领本土市场的关键。
总结
张建中的履历从科研机构到全球科技巨头，再到创立国产GPU企业，涵盖了IT行业的多个关键环节。他在英伟达期间积累的生态构建能力与本土化经验，为摩尔线程的发展奠定了基础；而其“造中国人自己的全功能GPU”的初心，则推动摩尔线程成为国产GPU领域的标杆企业。其职业生涯不仅见证了中国GPU产业的崛起，也为本土科技企业的发展提供了可借鉴的路径。
I. Basic Background: A Cadre-Trained IT Professional
Zhang Jianzhong was born in Nanjing, Jiangsu Province in 1966. He graduated from the Department of Computer Science at Nanjing University of Science and Technology with a bachelor’s degree, and later pursued a master’s degree at the former Metallurgical Ministry Automation Research Institute. His cadre-trained background laid a solid technical foundation for his subsequent career in the IT field.
II. Early Career: From Scientific Research to Enterprise, Accumulating Industry Experience
Zhang Jianzhong started his career at the National Computer Laboratory of the Metallurgical Automation Research and Design Institute. From May 1990 to March 1992, he served as a senior researcher, participating in scientific research projects at the laboratory and accumulating early technical research experience.
In April 1992, he joined Hewlett-Packard (HP) China as a Product General Manager, responsible for the market promotion and management of HP computer system products, where he accumulated experience in enterprise operations and product management.
In June 2001, Zhang Jianzhong transferred to Dell (China) Co., Ltd. as the General Manager of the Global Customer Department, responsible for product sales and customer relationship management for Dell’s global customers, further expanding his senior management experience in IT enterprises.
III. NVIDIA Period: Pioneering the Chinese Market, Becoming a Global Vice President
In 2005, Zhang Jianzhong joined NVIDIA, embarking on his core career in the GPU field. During his tenure at NVIDIA, he served as Global Vice President and General Manager of Greater China, responsible for the strategic planning and business expansion of NVIDIA’s Chinese market.
His core contribution lies in building a complete GPU ecosystem in China. By promoting cooperation between NVIDIA GPUs and Chinese domestic software and hardware manufacturers, as well as launching customized products for the Chinese market, he increased NVIDIA’s market share in China’s GPU market from less than 50% in 2008 to 80% in 2020, making NVIDIA the dominant brand in China’s GPU market. This achievement not only consolidated NVIDIA’s position in the global GPU field but also earned Zhang Jianzhong the reputation of a "China expert" in the GPU industry, accumulating rich local market resources and ecosystem construction experience.
IV. Founding Moore Threads: Pursuing the "Domestic GPU Dream" and Starting a Business
In 2020, Zhang Jianzhong left NVIDIA and founded Moore Threads Intelligent Technology (Beijing) Co., Ltd. (hereinafter referred to as "Moore Threads"), serving as Chairman and General Manager. His entrepreneurial初心 was to "build China’s own full-function GPU" to solve the "choke point" problem in China’s GPU industry.
After its establishment, Moore Threads rapidly advanced R&D under Zhang Jianzhong’s leadership: In November 2021, it launched its first full-function GPU chip, "Sudi"; in March 2022, it released the MUSA Unified System Architecture; in November 2022, it launched the industry’s first domestic gaming graphics card, MTT S80; in September 2023, it released the new-generation full-function GPU chip, "Quyuan," and the AI training and inference integrated computing card, MTT S4000, gradually building a full-function GPU product system covering 3D graphics rendering, AI computing, scientific computing, and other capabilities.
Under Zhang Jianzhong’s leadership, Moore Threads developed rapidly: In October 2023, it was listed on the U.S. Department of Commerce’s Entity List (restricting its access to U.S. technology and products), but the company adjusted its supply chain strategy (such as adopting domestic foundry) to promote independent controllability; On December 5, 2025, it was listed on the STAR Market, with its opening price rising more than 400% and its market value exceeding 300 billion yuan, becoming "China’s first domestic GPU stock."
V. Core Competencies and Contributions: Ecosystem Construction and Localization Experience
Zhang Jianzhong’s core competitiveness lies in his GPU ecosystem construction capabilities and localization market experience:
Ecosystem Construction: During his tenure at NVIDIA, he promoted the popularization of NVIDIA’s CUDA ecosystem in China, accumulating rich software ecosystem resources. After founding Moore Threads, he continued this approach, promoting the compatibility of the MUSA architecture with domestic software ecosystems (such as game engines and AI frameworks) and reducing developers’ migration costs.
Localization Experience: He is familiar with the needs of the Chinese market (such as gaming, AI, and industrial design) and can launch customized products for the local market (such as MTT S80 for gamers and MTT S4000 for AI enterprises), which is also the key to Moore Threads’ rapid capture of the local market.
Summary
Zhang Jianzhong’s career spans from scientific research institutions to global tech giants and then to founding a domestic GPU enterprise, covering multiple key links in the IT industry. His ecosystem construction capabilities and localization experience accumulated during his tenure at NVIDIA laid the foundation for the development of Moore Threads; his "dream of building China’s own full-function GPU" has promoted Moore Threads to become a benchmark enterprise in China’s GPU industry. His career not only witnessed the rise of China’s GPU industry but also provided a replicable path for the development of local tech enterprises.
(Note: The above content is translated from the original Chinese text, and all proper nouns, company names, product names, and data are consistent with the original. The English translation of technical terms such as "full-function GPU" and "MUSA Unified System Architecture" follows industry conventions and official statements from relevant companies.)
做多
做多
做多
做多
做多 
做多
做多
一天一家A股公司高管：百济神州生物科技有限公司董事长 欧雷强当资本成为诗行：一位企业掌舵者的价值投资叙事
一、基本信息
欧雷强（John V. Oyler），1969年出生，美国国籍，硕士研究生学历。他是全球创新药企百济神州（北京）生物科技有限公司的联合创始人、执行董事、董事会主席兼首席执行官（2010年至今），也是中国生物医药领域极具影响力的企业家之一。
二、教育背景
1990年：毕业于麻省理工学院（MIT），获理学学士学位（专业未明确提及，但早期职业生涯涉及机械工程与生物领域）。
1996年：毕业于斯坦福大学商学院，获工商管理硕士（MBA）学位。
三、职业生涯经历
欧雷强的职业生涯横跨咨询、创业与生物医药行业，核心经历如下：
1. 咨询行业起步（1990-1997年）
以管理顾问身份加入麦肯锡公司（McKinsey & Company），开启职业生涯。期间积累了战略规划、运营管理与商业咨询经验，为后续创业奠定了基础。
2. 首次进入生物医药行业（1997-1998年）
1997年至1998年，担任Genta Incorporated（纳斯达克上市、肿瘤重点生物制药企业）联席首席执行官。这段经历让他深入接触到生物医药企业的运营模式与研发流程。
3. 第一次创业：电信数据领域（1998-2002年）
1998年，离开Genta后创立Telephia, Inc.（信息商业公司，类似IMS/IQVIA，为决策提供数据服务），并担任总裁。2007年，Telephia以4.49亿美元被尼尔森公司（The Nielsen Company）收购，首次创业获得成功。
4. 回归生物医药：CRO领域创业（2002-2009年）
2002-2004年：担任Galenea Corp（中枢神经系统疾病治疗方法研发企业）首席执行官，积累了生物制药研发管理经验。
2005-2009年：创立BioDuro, LLC（药品开发外包公司，CRO领域），并担任总裁兼首席执行官。2009年，BioDuro以7700万美元被Pharmaceutical Product Development Inc.（PPD）收购。此次创业让他深刻理解了中国生物医药研发的成本优势与人才潜力，为后续进入中国市场埋下伏笔。
5. 联合创立百济神州（2010年至今）
2010年，与王晓东（美国科学院院士、北京生命科学研究所所长）共同创立百济神州（北京）生物科技有限公司，并担任执行董事、董事会主席兼首席执行官。百济神州聚焦肿瘤创新药研发，先后推出百悦泽（泽布替尼，BTK抑制剂）、百泽安（替雷利珠单抗，PD-1抑制剂）等核心产品，成为中国生物医药领域的标杆企业。2019年，欧雷强入选生物技术产业协会（BIO）董事会及其卫生部门理事会，深度参与全球生物医药政策制定。
四、核心成就与荣誉
百济神州发展：带领百济神州从初创企业成长为全球性创新药企，其核心产品百悦泽（泽布替尼）成为全球同类药物领导者，覆盖70多个市场；百泽安（替雷利珠单抗）在中国获批多个适应症，推动中国创新药纳入医保。
行业认可：2019年入选BIO董事会及卫生部门理事会，成为全球生物医药行业的重要参与者；其创业经历被多家媒体报道，成为中国生物医药领域的典型案例。
五、总结
欧雷强的职业生涯以“跨领域、国际化、创新”为核心标签：从咨询到电信，再回归生物医药，每一次转型都抓住了时代机遇；其创业经历覆盖美国与中国市场，深刻理解全球生物医药行业的趋势与需求；作为百济神州的掌舵人，他带领企业实现了从0到1的突破，成为中国创新药走向世界的代表。
John V. Oyler's Professional Profile
I. Basic Information
John V. Oyler, born in 1969, is an American entrepreneur with a master’s degree. He serves as the Co-founder, Executive Director, Board Chairman, and Chief Executive Officer (CEO) of BeiGene (Beijing) Co., Ltd., a global innovative biopharmaceutical company, since 2010. He is widely regarded as one of the most influential entrepreneurs in China’s biopharmaceutical industry.
II. Educational Background
1990: Graduated from the Massachusetts Institute of Technology (MIT) with a Bachelor of Science (B.S.) in an unspecified discipline, though his early career involved mechanical engineering and biology.
1996: Earned a Master of Business Administration (MBA) from Stanford University Graduate School of Business.
III. Professional Career
John Oyler’s career spans consulting, entrepreneurship, and the biopharmaceutical industry, with a clear focus on innovation and global expansion.
1. Consulting: Laying the Foundation (1990–1997)
He began his career as a management consultant at McKinsey & Company, where he gained expertise in strategic planning, operational management, and business consulting—skills that would later underpin his entrepreneurial ventures.
2. Early Biopharmaceutical Experience: Genta Incorporated (1997–1998)
In 1997, Oyler joined Genta Incorporated, a Nasdaq-listed biopharmaceutical company focused on oncology, as Co-Chief Executive Officer (Co-CEO). This role provided him with hands-on experience in the operations and R&D processes of a biotech firm.
3. First Entrepreneurship: Telephia, Inc. (1998–2002)
In 1998, Oyler left Genta to found Telephia, Inc., a data analytics company akin to IMS Health/IQVIA, which provided decision-support data to the pharmaceutical industry. He served as President of Telephia until its acquisition by The Nielsen Company in 2007 for $449 million—a successful exit that marked his first major entrepreneurial achievement.
4. Second Entrepreneurship: BioDuro, LLC (2002–2009)
Between 2002 and 2004, Oyler served as CEO of Galenea Corp, a biotech firm developing treatments for central nervous system (CNS) disorders, further deepening his expertise in biopharmaceutical R&D management.
In 2005, he founded BioDuro, LLC, a contract research organization (CRO) focused on drug development. As President and CEO, he led BioDuro to become a leading player in the CRO space, with its 2009 acquisition by Pharmaceutical Product Development, Inc. (PPD) for $77 million solidifying his reputation as a successful biotech entrepreneur. This experience also exposed him to the cost advantages and talent pool of China’s biopharmaceutical industry, planting the seeds for his future focus on the Chinese market.
5. Co-founding BeiGene: Leading China’s Biopharmaceutical Rise (2010–Present)
In 2010, Oyler partnered with Wang Xiaodong (a member of the U.S. National Academy of Sciences and President of the Beijing Institute of Life Science) to co-found BeiGene (Beijing) Co., Ltd., a company dedicated to developing innovative oncology drugs. As Executive Director, Board Chairman, and CEO, he has led BeiGene from a startup to a global leader in biopharmaceuticals.
Under his leadership, BeiGene has launched two blockbuster products:
BRUKINSA® (zanubrutinib): A BTK inhibitor for lymphoma, which has been approved in over 70 markets worldwide and became the first Chinese-developed oncology drug to receive accelerated approval from the U.S. Food and Drug Administration (FDA).
TEVIMBRA® (tislelizumab): A PD-1 inhibitor for solid tumors, which has been approved in multiple countries, including China, the U.S., and the European Union (EU).
Oyler’s global vision has been instrumental in BeiGene’s expansion: the company established its first U.S. clinical research and production base in New Jersey in 2024 and continues to advance a pipeline of innovative therapies for cancer and other diseases.
In 2019, he was elected to the Board of Directors of the Biotechnology Innovation Organization (BIO) and its Health Section Board, further cementing his role as a key player in the global biopharmaceutical industry.
IV. Key Achievements and Honors
Leadership at BeiGene: Transformed BeiGene from a startup into a global innovative biopharmaceutical company, with products approved in over 70 markets and a pipeline of over 20 clinical-stage candidates.
Industry Recognition: Elected to the BIO Board of Directors in 2019, becoming one of the few Chinese entrepreneurs to hold such a position in a leading global biotech organization.
Global Impact: Led BeiGene to become the first Chinese company to launch an oncology drug (BRUKINSA®) in the U.S. via the accelerated approval pathway, setting a precedent for Chinese biotech firms entering the global market.
V. Summary
John Oyler’s career is defined by cross-industry expertise, international perspective, and a commitment to innovation. From consulting to entrepreneurship in telecom and biopharmaceuticals, each phase of his career has been marked by a focus on solving complex problems and creating value. As the leader of BeiGene, he has not only built a successful global company but also helped position China as a key player in the global biopharmaceutical industry. His experience and vision make him a respected figure among entrepreneurs and industry leaders worldwide.
(All information is based on public sources, including BeiGene’s official announcements, media reports, and industry databases.) 
做多
